HDAC-IN-36

Modify Date: 2024-04-06 19:16:54

HDAC-IN-36 structure	Common Name	HDAC-IN-36
	CAS Number	2482992-54-9	Molecular Weight	537.65
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₉H₃₉N₅O₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of HDAC-IN-36

HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research[1].

Name	HDAC-IN-36

Description	HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	HDAC6:11.68 nM (IC50) HDAC10:13.24 nM (IC50) HDAC3:79.17 nM (IC50) HDAC1:86.93 nM (IC50) HDAC2:97.32 nM (IC50) HDAC8:378.2 nM (IC50) HDAC4:>1000 nM (IC50) HDAC5:>1000 nM (IC50) HDAC7:>1000 nM (IC50) HDAC9:>1000 nM (IC50) HDAC11:>1000 nM (IC50)
In Vitro	HDAC-IN-36 (compound 23 g) (0-10, 24 h) exhibits good antiproliferative activity in MDA-MB-231 cells, promotes the acetylation of α-Tubulin and HSP90[1]. HDAC-IN-36 (0-10, 24 h) induces apoptosis in MDA-MB-231 cells in a dose-dependent manner, and mainly induces mitochondrial-dependent apoptosis[1]. HDAC-IN-36 (0-10, 24 h) inhibits MDA-MB-231 cells migration in a dose-dependent manner, increases the expression of E-cadherin and decreases the expression of MMP-2 obviously[1]. HDAC-IN-36 (0-10, 24 h) induces noteworthy autophagy, increases the expression of Beclin1, LC3II and decreases the expression of SQSTM1/p62[1]. Cell Viability Assay Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Exhibited good anti-proliferative activity in MDA-MB-231 cells, with IC50 of 1.32 ± 0.13 μM, increased the acetylation level of intracellular proteins, and promoted the acetylation of α-Tubulin and HSP90. Apoptosis Analysis Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Induced apoptosis in MDA-MB-231 cells in a dose-dependent manner. Cell Autophagy Assay Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Induced noteworthy autophagy with increased aggregation of LC3 puncta. Western Blot Analysis Cell Line: MDA-MB-231 cells[1] Concentration: 0, 2.5, 5, 10 μM Incubation Time: 24 h Result: Mainly induced mitochondrial-dependent apoptosis, up-regulated the expression of Bax and downregulated the expression of Bcl-2, and increased the cleavage of caspase3, caspase8 and caspase9; increased the expression of E-cadherin and decreased the expression of MMP-2 obviously; increased the expression of Beclin1, LC3II and decreased the expression of SQSTM1/p62.
In Vivo	HDAC-IN-36 (compound 23 g) (Zebrafish tumor xenograft model; 0-5 μg/mL, 3 days) shows potent anti-tumor and anti-metastatic activity, and improves in vivo anti-tumor efficacy[1]. HDAC-IN-36 (Beagles, 20 mg/kg, Orally, once) shows a significant improvement in pharmacokinetic parameters[1]. Pharmacokinetic Parameters of HDAC-IN-36 in male Beagles[1]. Parameters 23g (20 mg/kg) T1/2 (h) 1.24 ± 0.21 Tmax (h) 0.79 ± 0.33 Cmax (μg/L) 120.36 ± 15.53 AUC0-t (μg/L∗h) 1275.35 ± 70.17 AUC0-∞ (μg/L∗h) 1289.40 ± 88.91 Animal Model: Zebrafish (MDA-MB-231-derived xenograft model, Wild-type AB strain)[1] Dosage: 0, 2.5, 5 μg/mL Administration: 3 days Result: Inhibited tumor formation and migration in a dose-dependent manner, and improved in vivo anti-tumor efficacy. Animal Model: Beagles (female, 8-10 kg, n = 4)[1] Dosage: 20 mg/kg (dissolved 0.5% sodium carboxyl methyl cellulose (CMC-Na) aqueous solution) Administration: Orally, once (Pharmacokinetic Analysis) Result: Showed a significant improvement in pharmacokinetic parameters with T1/2 value of 1.24 h.
References	[1]. Yao D, Li C, Jiang J, et al. Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. Eur J Med Chem. 2020;205:112648.

Molecular Formula	C₂₉H₃₉N₅O₅
Molecular Weight	537.65

HDAC-IN-36

Use of HDAC-IN-36

Names

HDAC-IN-36 Biological Activity

Chemical & Physical Properties